Melane Sampson, Author at BioTuesdays

Developments

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...

March 24, 2025

Developments

First patients recruited into Ondine’s Steriwave ICU pilot study

Ondine Biomedical (LON:OBI) announced the initiation of patient recruitment for an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. The company states that...

March 20, 2025

Developments

USPO issues NOA to Sonnet for second IL-18 protein patent

Sonnet BioTherapeutics (NASDAQ:SONN) announced that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) for a second patent in the IL-18 variant protein field. According to...

March 19, 2025

Developments

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Bioxytran (QTCQB:BIXT) announced that it has signed a non-disclosure agreement (NDA) with the board of regents of the University System of Georgia, University of Georgia (UGA), to collaborate on evaluating its galectin...

March 19, 2025

Developments

Final patient enrolled in Biofrontera’s Phase 3 trial of Ameluz in AKs

Biofrontera (NASDAQ:BFRI) announced completion of patient enrollment in the Phase 3 study of Ameluz topical gel for the treatment of Actinic Keratoses (AKs) on the extremities, neck, and trunk with photodynamic therapy...

March 18, 2025

Feature

Future Fields fueling custom protein biomanufacturing with the power of fruit flies

Closely held Future Fields is spearheading the world’s first synthetic biology system with an innovative transgenic bug-based approach—leveraging fruit flies to combine genetic engineering with insect farming to unlock...

March 18, 2025

Developments

Capricor reveals positive data from HOPE-2 trial of deramiocel in DMD

Capricor Therapeutics (NASDAQ:CAPR) announced positive long-term data from its on-going HOPE-2 trial demonstrating the potential of its lead candidate, deramiocel, to slow disease progression and preserve upper limb...

March 17, 2025

Developments

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that it has filed a premarket approval (PMA) application for its next-generation B-Series OCT system, which combines proprietary AI technology with optical...

March 17, 2025

Developments

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Biovica International (STO:BIOVIC-B; FRA:911) announced that it has partnered with Outcomes4Me to support post-menopausal patients with hormone (HR)-positive metastatic breast cancer (mBC) in understanding treatment...

March 12, 2025

Executive Moves

Matinas names Keith Murphy and Edward Neugeboren to BOD

Matinas BioPharma (NYSE American:MTNB) has appointed biotech industry veterans Keith Murphy and Edward Neugeboren to its board of directors (BOD) as independent members, effective today. Also effective today, Matinas...

March 11, 2025

Author - Melane Sampson

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

First patients recruited into Ondine’s Steriwave ICU pilot study

USPO issues NOA to Sonnet for second IL-18 protein patent

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Final patient enrolled in Biofrontera’s Phase 3 trial of Ameluz in AKs

Future Fields fueling custom protein biomanufacturing with the power of fruit flies

Capricor reveals positive data from HOPE-2 trial of deramiocel in DMD

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Matinas names Keith Murphy and Edward Neugeboren to BOD

Subscribe